Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Quality of Life Research
Erschienen in: Quality of Life Research 4/2010

01.05.2010 | Brief Communication

Responsiveness of the EQ-5D and 8-item Parkinson’s Disease Questionnaire (PDQ-8) in a 4-year follow-up study

verfasst von: Nan Luo, Wai-Yee Ng, Puay-Ngoh Lau, Wing-Lok Au, Louis CS Tan

Erschienen in: Quality of Life Research | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective

The purpose of this study was to evaluate the responsiveness of the EQ-5D and the Parkinson’s Disease Questionnaire (PDQ-8) to deterioration in health-related quality of life (HRQoL) in patients with Parkinson’s disease (PD).

Methods

HRQoL and clinical data collected from 31 patients with PD (male: 74.2%, mean age: 61 years) who were surveyed with the EQ-5D and the PDQ-8 questionnaires in 2002 and 2006/2007 were analyzed. Responsiveness of the EQ-5D, PDQ-8, and Hoehn and Yahr (H&Y) staging were assessed according to Cohen’s effect size (ES) and standardized response mean (SRM).

Results

The mean (standard deviation) EQ-5D index and PDQ-8 summary index (PDQ-8SI) scores were 0.76 (0.23) and 17.7 (14.2) at baseline and 0.52 (0.33) and 35.1 (17.4) at year four. Based on both ES and SRM indices, the rank order of responsiveness of the studied measures, from high to low, was PDQ-8SI (ES = 1.22), EQ-5D index score (ES = 1.06), H&Y score (ES = 0.82), and the EQ-VAS score (ES = 0.24).

Conclusion

Both the EQ-5D and PDQ-8 are responsive to changes in health burden of the Parkinson’s disease over a 4-year period.
Literatur
1.
Gold, M. R., Patrick, D. L., Torrance, D. G., et al. (1996). Identifying and valuing outcomes. In M. R. Gold (Ed.), Cost-effectiveness in health and medicine (pp. 82–134). New York, NY: Oxford University Pres.
2.
Drummond, M. F., O’ Brien, B. J., & Stoddart, G. L. (1997). Cost-utility analysis. In: Methods for the economic evaluation of health care programmes (2nd ed.). Oxford: Oxford University Press, pp 139–199.
3.
Schrag, A., Selai, C., Jahanshahi, M., & Quinn, N. P. (2000). The EQ-5D–a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 69, 67–73.CrossRef
4.
Luo, N., Low, S., Lau, P. N., Au, W. L., & Tan, L. C. S. (2009). Is EQ-5D a valid quality of life instrument in patients with Parkinson’s disease? A study in Singapore. Annals of the Academy of Medicine, Singapore, 38, 521–528.PubMed
5.
Reuther, M., Spottke, E. A., & Klotsche, J. (2007). Assessing health-related quality of life in patients with Parkinson’s disease in a prospective longitudinal study. Parkinsonism & Related Disorders, 13, 108–114.CrossRef
6.
Noyes, K., Dick, A. W., Holloway, R. G., & Parkinson Study Group. (2006). Pramipexole versus levodopa in patients with early Parkinson’s disease: Effect on generic and disease-specific quality of life. Value Health, 9, 28–38.CrossRefPubMed
7.
Schrag, A., Spottke, A., Quinn, N. P., & Dodel, R. (2009). Comparative responsiveness of Parkinson’s disease scales to change over time. Movement Disorders, 24, 813–818.CrossRefPubMed
8.
Noyes, K., Dick, A. W., Holloway, R. G., & Group, Parkinson. Study. (2004). Pramipexole v. levodopa as initial treatment for Parkinson’s disease: A randomized clinical-economic trial. Medical Decision Making, 24, 472–485.CrossRefPubMed
9.
Reichmann, H., Boas, J., Macmahon, D., Myllyla, V., Hakala, A., Reinikainen, K., et al. (2005). Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurologica Scandinavica, 111, 21–28.CrossRefPubMed
10.
Karlsen, K. H., Tandberg, E., Arsland, D., & Larsen, J. P. (2000). Health related quality of life in Parkinson’s disease: A prospective longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 69, 584–589.CrossRef
11.
Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., & Hyman, N. (1997). The PDQ-8: Development and validation of a short-form Parkinson’s disease questionnaire. Psychology Health, 12, 805–814.CrossRef
12.
Tan, L. C. S., Luo, N., Nazri, M., Li, S. C., & Thumboo, J. (2004). Validity and reliability of the PDQ-39 and PDQ-8 in English-speaking patients in Singapore. Parkinsonism & Related Disorders, 10, 493–499.CrossRef
13.
Tan, L. C., Lau, P. N., Au, W. L., & Luo, N. (2007). Validation of PDQ-8 as an independent instrument in English and Chinese. Journal of the Neurological Sciences, 255, 77–80.CrossRefPubMed
14.
Gelb, D. J., Oliver, E., & Gilman, S. (1999). Diagnostic criteria for Parkinson disease. Archives of Neurology, 56, 33–39.CrossRefPubMed
15.
Fahn, S., Marsden, C. D., Calne, D. B., & Goldstein, M. (Eds.). (1987). Recent developments in Parkinson’s Disease (Vol. 2, pp. 153–163). Florham Park, NJ: Macmillan Health Care Information.
16.
Peto, V., Jenkinson, C., & Fitzpatrick, R. (1998). PDQ-39: A review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. Journal of Neurology, 245(suppl 1), S10–S14.CrossRefPubMed
17.
Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35, 1095–1108.CrossRefPubMed
18.
Fayers, P. M., & Machin, D. (2000). Quality of life: Assessment analysis and interpretation. Chichester: Wiley.
19.
Cohen, J. (1998). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale: Lawrence Earlbaum Associates.
20.
Luo, N., Tan, L. C., Zhao, Y., Lau, P. N., Au, W. L., Li, S. C., et al. (2009). Determination of the longitudinal validity and minimally important difference of the 8-item Parkinson’s Disease Questionnaire (PDQ-8). Movement Disorders, 24, 183–187.CrossRefPubMed
Metadaten
Titel
Responsiveness of the EQ-5D and 8-item Parkinson’s Disease Questionnaire (PDQ-8) in a 4-year follow-up study
verfasst von
Nan Luo
Wai-Yee Ng
Puay-Ngoh Lau
Wing-Lok Au
Louis CS Tan
Publikationsdatum
01.05.2010
Verlag
Springer Netherlands
Erschienen in
Quality of Life Research / Ausgabe 4/2010
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-010-9615-7

Weitere Artikel der Ausgabe 4/2010

Quality of Life Research 4/2010 Zur Ausgabe

OriginalPaper

Restless legs syndrome and its relationship with anxiety, depression, and quality of life in cancer patients undergoing chemotherapy

OriginalPaper

Retracted Article: Association of physical fitness with health-related quality of life in Finnish young men

OriginalPaper

An item response analysis of the pediatric PROMIS anxiety and depressive symptoms scales

OriginalPaper

Sampling plan and patient characteristics of the PROMIS pediatrics large-scale survey

OriginalPaper

Development of the WHOQOL disabilities module

Brief Communication

No negative effects of a multi-factorial, intensified treatment on self-reported health status, treatment satisfaction, and diabetes-related distress in screen-detected type 2 diabetes patients. The ADDITION-Netherlands study